261 related articles for article (PubMed ID: 29551913)
1. Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.
Venturelli M; Guaitoli G; Omarini C; Moscetti L
Breast Cancer (Dove Med Press); 2018; 10():39-49. PubMed ID: 29551913
[TBL] [Abstract][Full Text] [Related]
2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
4. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
5. [LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?].
Daguenet E; Jmour O; Vallard A; Guy JB; Jacquin JP; Méry B; Magné N
Bull Cancer; 2019 Apr; 106(4):342-353. PubMed ID: 30853114
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Hubalek M; Brantner C; Marth C
Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
8. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
9. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
Tancredi R; Furlanetto J; Loibl S
Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.
Lu YS; Wong A; Kim HJ
Front Oncol; 2021; 11():700722. PubMed ID: 34595110
[TBL] [Abstract][Full Text] [Related]
11. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
12. [LHRH analogs: current role in early and advanced breast cancer treatment of premenopausal patients.].
Fabi A; Catania G
Recenti Prog Med; 2019; 110(7):347-355. PubMed ID: 31379370
[TBL] [Abstract][Full Text] [Related]
13. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Emens LA; Davidson NE
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
[TBL] [Abstract][Full Text] [Related]
16. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
17. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
18. Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.
Park WC
J Breast Cancer; 2016 Dec; 19(4):341-348. PubMed ID: 28053622
[TBL] [Abstract][Full Text] [Related]
19. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases.
Madeddu C; Gramignano G; Kotsonis P; Paribello F; Macciò A
Oncol Lett; 2014 Sep; 8(3):1279-1282. PubMed ID: 25120706
[TBL] [Abstract][Full Text] [Related]
20. Evaluating triptorelin as a treatment option for breast cancer.
Ferraro E; Trapani D; Marrucci E; Curigliano G
Expert Opin Pharmacother; 2019 Oct; 20(15):1809-1818. PubMed ID: 31500470
[No Abstract] [Full Text] [Related]
[Next] [New Search]